RxDoctor Payments Data

Tonja Austin, MD

Family Medicine · Tinley Park, ILNPI 1558375030

Payments from drug & device makers

$739in general payments, 2019–2025

Across 23 payments — averaging $32.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$128
  • Lilly USA, LLC$123
  • E.r. Squibb & Sons, L.L.C.$108
  • Pfizer$94
  • Novo Nordisk$94
  • Cranial Technologies, Inc$60
  • plus $133 from 6 others

What the payments were for

  • Food & beverage$739100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$739 in reported general payments places this provider in the 70th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$68,531
Medicare patients
285
Services billed
767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$40,881
JanuviaSitagliptin Phosphate32$32,633
JardianceEmpagliflozin19$27,163
MounjaroTirzepatide14$18,691
Breo ElliptaFluticasone/Vilanterol11$7,274
NorvascAmlodipine Besylate11$2,618
Celecoxib19$1,867
SynthroidLevothyroxine Sodium24$1,537
Atorvastatin Calcium122$1,527
Albuterol Sulfate HfaAlbuterol Sulfate39$1,309
Losartan Potassium85$1,132
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide21$896
Amlodipine Besylate131$889
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide13$637
Rosuvastatin Calcium64$634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$94$40,88141 claims
Lilly USA, LLCMounjaro$123$18,69114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Tinley Park

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →